全文获取类型
收费全文 | 5638篇 |
免费 | 330篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 202篇 |
妇产科学 | 71篇 |
基础医学 | 557篇 |
口腔科学 | 241篇 |
临床医学 | 548篇 |
内科学 | 1994篇 |
皮肤病学 | 36篇 |
神经病学 | 221篇 |
特种医学 | 580篇 |
外科学 | 519篇 |
综合类 | 97篇 |
一般理论 | 2篇 |
预防医学 | 408篇 |
眼科学 | 125篇 |
药学 | 191篇 |
中国医学 | 4篇 |
肿瘤学 | 185篇 |
出版年
2023年 | 22篇 |
2022年 | 23篇 |
2021年 | 78篇 |
2020年 | 37篇 |
2019年 | 78篇 |
2018年 | 130篇 |
2017年 | 64篇 |
2016年 | 80篇 |
2015年 | 107篇 |
2014年 | 162篇 |
2013年 | 227篇 |
2012年 | 297篇 |
2011年 | 321篇 |
2010年 | 266篇 |
2009年 | 201篇 |
2008年 | 288篇 |
2007年 | 326篇 |
2006年 | 259篇 |
2005年 | 266篇 |
2004年 | 249篇 |
2003年 | 227篇 |
2002年 | 206篇 |
2001年 | 69篇 |
2000年 | 72篇 |
1999年 | 64篇 |
1998年 | 171篇 |
1997年 | 148篇 |
1996年 | 141篇 |
1995年 | 104篇 |
1994年 | 95篇 |
1993年 | 108篇 |
1992年 | 60篇 |
1991年 | 57篇 |
1990年 | 49篇 |
1989年 | 84篇 |
1988年 | 77篇 |
1987年 | 75篇 |
1986年 | 69篇 |
1985年 | 73篇 |
1984年 | 46篇 |
1983年 | 48篇 |
1982年 | 56篇 |
1981年 | 32篇 |
1980年 | 51篇 |
1979年 | 29篇 |
1978年 | 33篇 |
1977年 | 34篇 |
1976年 | 34篇 |
1975年 | 38篇 |
1973年 | 20篇 |
排序方式: 共有6003条查询结果,搜索用时 15 毫秒
101.
102.
A humanised tissue‐engineered bone model allows species‐specific breast cancer‐related bone metastasis in vivo 下载免费PDF全文
VMC Quent AV Taubenberger JC Reichert LC Martine JA Clements DW Hutmacher D Loessner 《Journal of tissue engineering and regenerative medicine》2018,12(2):494-504
Bone metastases frequently occur in the advanced stages of breast cancer. At this stage, the disease is deemed incurable. To date, the mechanisms of breast cancer‐related metastasis to bone are poorly understood. This may be attributed to the lack of appropriate animal models to investigate the complex cancer cell–bone interactions. In this study, two established tissue‐engineered bone constructs (TEBCs) were applied to a breast cancer‐related metastasis model. A cylindrical medical‐grade polycaprolactone‐tricalcium phosphate scaffold produced by fused deposition modelling (scaffold 1) was compared with a tubular calcium phosphate‐coated polycaprolactone scaffold fabricated by solution electrospinning (scaffold 2) for their potential to generate ectopic humanised bone in NOD/SCID mice. While scaffold 1 was found not suitable to generate a sufficient amount of ectopic bone tissue due to poor ectopic integration, scaffold 2 showed excellent integration into the host tissue, leading to bone formation. To mimic breast cancer cell colonisation to the bone, MDA‐MB‐231, SUM1315, and MDA‐MB‐231BO breast cancer cells were cultured in polyethylene glycol‐based hydrogels and implanted adjacent to the TEBCs. Histological analysis indicated that the breast cancer cells induced an osteoclastic reaction in the TEBCs, demonstrating analogies to breast cancer‐related bone metastasis seen in patients. 相似文献
103.
Heather D. Simister Gregg A. Tkachuk Barbara L. Shay Norah Vincent Joseph J. Pear Ryan Q. Skrabek 《The journal of pain》2018,19(7):741-753
In this study, 67 participants (95% female) with fibromyalgia (FM) were randomly assigned to an online acceptance and commitment therapy (online ACT)?and?treatment as usual (TAU; ACT + TAU) protocol or a TAU control condition. Online ACT?+?TAU participants were asked to complete 7 modules over an 8-week period. Assessments were completed at pre-treatment, post-treatment, and 3-month follow-up periods and included measures of FM impact (primary outcome), depression, pain, sleep, 6-minute walk, sit to stand, pain acceptance (primary process variable), mindfulness, cognitive fusion, valued living, kinesiophobia, and pain catastrophizing. The results indicated that online ACT?+?TAU participants significantly improved in FM impact, relative to TAU (P?<.001), with large between condition effect sizes at post-treatment (1.26) and follow-up (1.59). Increases in pain acceptance significantly mediated these improvements (P?=?.005). Significant improvements in favor of online ACT?+?TAU were also found on measures of depression (P?=?.02), pain (P?=?.01), and kinesiophobia (P?=?.001). Although preliminary, this study highlights the potential for online ACT to be an efficacious, accessible, and cost-effective treatment for people with FM and other chronic pain conditions.
Perspective
Online ACT reduced FM impact relative to a TAU control condition in this randomized controlled trial. Reductions in FM impact were mediated by improvements in pain acceptance. Online ACT appears to be a promising intervention for FM. 相似文献104.
Dietary restraint of 5‐year‐old girls: Associations with internalization of the thin ideal and maternal,media, and peer influences 下载免费PDF全文
105.
106.
107.
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction 总被引:3,自引:0,他引:3
Heidenreich PA Gubens MA Fonarow GC Konstam MA Stevenson LW Shekelle PG 《Journal of the American College of Cardiology》2004,43(6):1019-1026
OBJECTIVES: This study was designed to evaluate the cost-effectiveness of screening patients with a B-type natriuretic peptide (BNP) blood test to identify those with depressed left ventricular systolic function. BACKGROUND: Asymptomatic patients with depressed ejection fraction (EF) may have less progression to heart failure if they can be identified and treated. METHODS: We used a decision model to estimate economic and health outcomes for different screening strategies using BNP and echocardiography to detect left ventricular EF <40% for men and women age 60 years. We used published data from community cohorts (gender-specific BNP test characteristics, prevalence of depressed EF) and randomized trials (benefit from treatment). RESULTS: Screening 1,000 asymptomatic patients with BNP followed by echocardiography in those with an abnormal test increased the lifetime cost of care (176,000 US dollars for men, 101,000 US dollars for women) and improved outcome (7.9 quality-adjusted life years [QALYs] for men, 1.3 QALYs for women), resulting in a cost per QALY of 22,300 US dollars for men and 77,700 US dollars for women. For populations with a prevalence of depressed EF of at least 1%, screening with BNP followed by echocardiography increased outcome at a cost < 50,000 US dollars per QALY gained. Screening would not be attractive if a diagnosis of left ventricular dysfunction led to significant decreases in quality of life or income. CONCLUSIONS: Screening populations with a 1% prevalence of reduced EF (men at age 60 years) with BNP followed by echocardiography should provide a health benefit at a cost that is comparable to or less than other accepted health interventions. 相似文献
108.
Oren Zusman Gregg S. Pressman Shmuel Banai Ariel Finkelstein Yan Topilsky 《JACC: Cardiovascular Imaging》2018,11(9):1225-1232
Objectives
The purpose of this study was to describe patients with severe symptomatic aortic stenosis with normal flow and low gradients and determine whether they benefit from intervention.Background
Severe symptomatic aortic stenosis is a progressive disease with high mortality. Although surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) are indicated for patients with high gradients (>40 mm Hg) or low gradients due to low flow, the approach for patients with normal flow and low gradients is poorly defined.Methods
Consecutive adult patients who underwent echocardiography between 2012 and 2015 at Tel-Aviv Medical Center and had an aortic valve area of ≤1.0 cm2, a mean gradient of <40 mm Hg, a stroke volume index of >35 ml/m2, and symptoms formed the study group. Patients designated for intervention (SAVR or TAVR) had their procedure within 6 months of the echocardiogram; the others were treated conservatively. The endpoints were all-cause mortality and cardiac-related mortality.Results
During the study period, 1,358 patients with an aortic valve area of ≤1.0 cm2 and symptoms were identified; 34% of these had normal flow and low gradient aortic stenosis and 303 were included. After mean follow-up of 652 days, 60 patients (20%) had died, with overall mortality rates of 28%, 10%, and 12% for conservatively treated, TAVR, and SAVR patients, respectively (p < 0.001). Using Cox regression with adjustment for other variables, TAVR was associated with improved survival versus conservative treatment (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.26 to 0.93; p = 0.03), and lower cardiac mortality (HR: 0.30; 95% CI: 0.10 to 0.74; p = 0.007) with no significant difference for SAVR versus TAVR. After propensity score matching of TAVR and conservatively treated patients, 25 of 94 (28%) conservatively treated and 10 of 94 (12%) TAVR patients had died (p = 0.016). In the matched cohort, Cox regression showed that TAVR had a significant association with improved survival (HR: 0.42; 95% CI: 0.20 to 0.86; p = 0.03).Conclusions
Symptomatic patients with an aortic valve area of ≤1.0 cm2, normal flow, and low gradient may benefit from intervention as opposed to conservative treatment. 相似文献109.
Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction 总被引:9,自引:0,他引:9
Harjai KJ Stone GW Boura J Mattos L Chandra H Cox D Grines L O'Neill W Grines C;Primary Angioplasty in Myocardial Infarction Investigators 《The American journal of cardiology》2003,91(9):1041-1045
We sought to determine whether diabetes mellitus independently conferred poor prognosis in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). In 3,742 patients enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI) studies with the intention of undergoing primary PCI, we compared in-hospital mortality, 6-month mortality, and 6-month major adverse cardiovascular events (MACEs), i.e., composite of death, reinfarction, or ischemic target vessel revascularization (TVR), between diabetics (n = 626, 17%) and nondiabetics (n = 3,116, 83%). We evaluated the independent impact of diabetes on outcomes after adjustment for baseline clinical and angiographic differences. Diabetics had worse baseline clinical characteristics, longer pain onset-to-hospital arrival time, and longer door-to-balloon time. They had more multivessel coronary disease and lower left ventricular ejection fractions, but better baseline Thrombolysis In Myocardial Infarction (TIMI) flow. Diabetics underwent primary PCI less often (88% vs 91%, p = 0.01). During the index hospitalization, diabetics were more likely to die (4.6% vs 2.6%, p = 0.005). During 6-month follow-up, diabetics had higher incidences of death (8.1% vs 4.2%, p <0.0001) and MACEs (18% vs 14%, p = 0.036). In multivariate analysis, diabetes was independently associated with 6-month mortality (hazard ratio 1.53, 95% confidence interval 1.03 to 2.26, p = 0.03), but not with in-hospital mortality or 6-month MACEs. We conclude that diabetics with AMI have less favorable baseline characteristics and are less likely to undergo primary PCI than nondiabetics. Despite excellent angiographic results, diabetics had significantly worse 6-month mortality. 相似文献
110.
Chung AK Pang PS Fonarow GC Gheorghiade M 《Current treatment options in cardiovascular medicine》2008,10(4):349-357
Hospitalization for acute heart failure syndromes (AHFS) is a significant negative predictor of prognosis. Although patients' presenting symptoms generally improve throughout hospitalization in response to therapy, post-discharge event rates, defined as rehospitalization and/or mortality, remain unacceptably high. In the past decade, many lifesaving therapies for heart failure, such as beta-blockers, aldosterone antagonists, and cardiac resynchronization therapy (CRT), have been defined. Hospitalization presents a unique opportunity to implement these and other lifesaving therapies. However, these opportunities are often missed, perhaps because the traditional focus of hospitalization has been on symptom relief, not improvement of post-discharge outcomes. Although many therapies are now available, each needs to be tailored to each patient based on a proper assessment (eg, revascularization for those with severe coronary artery disease, CRT for those with wide QRS). Thorough cardiac assessment combined with tailored implementation may improve post-discharge outcomes. New strategies are needed to improve uptake of current best-evidence therapies to decrease the morbidity and mortality of AHFS. 相似文献